Cargando…
Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%
BACKGROUND: Immune checkpoint inhibitor (ICI) monotherapy is currently approved for the treatment of advanced non‐small cell lung cancer (NSCLC) patients with programmed death ligand‐1 (PD‐L1) expression ≥50%. However, the efficacy of ICI monotherapy in patients with PD‐L1 expression <50% has not...
Autores principales: | Takahara, Yutaka, Abe, Ryudai, Sumito, Nagae, Tanaka, Takuya, Ishige, Yoko, Shionoya, Ikuyo, Yamamura, Kouichi, Nishiki, Kazuaki, Nojiri, Masafumi, Kato, Ryo, Shinomiya, Shohei, Oikawa, Taku |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518233/ https://www.ncbi.nlm.nih.gov/pubmed/37536667 http://dx.doi.org/10.1111/1759-7714.15059 |
Ejemplares similares
-
Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2022) -
Differential response in patients with large cell neuroendocrine carcinoma of the lung to initial therapy: A case series
por: Takahara, Yutaka, et al.
Publicado: (2022) -
Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy
por: Takahara, Yutaka, et al.
Publicado: (2022) -
Influencing factors of efficacy and long‐term use of amrubicin in patients with small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2023) -
Risk factors for acute exacerbation in lung cancer complicated by interstitial lung disease with slight reticular shadows
por: Takahara, Yutaka, et al.
Publicado: (2021)